Article
Human immunodeficiency virus type 1 reverse transcriptase genotype and drug susceptibility changes in infected individuals receiving dideoxyinosine monotherapy for 1 to 2 years.
Antimicrobial agents and chemotherapy - 1 Apr 1997
Winters M A, Shafer R W, Jellinger R A, Mamtora G, Gingeras T, Merigan T C
Abstract excerpt
The genetic mechanisms of human immunodeficiency virus type 1 (HIV-1) resistance to dideoxyinosine (ddI) in vivo have been described based on data from primary HIV-1 isolates. To better define the spectrum of HIV-1 reverse transcriptase (RT) changes occurring during ddI therapy, we determined the genotype and ddI susceptibility of the RT gene of HIV RNA isolated from the plasma of 23 patients who had received 1...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.